These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11750352)

  • 1. Pharmacodynamic monitoring of lymphocyte proliferation and TGF-beta 1 expression at cyclosporine a (CyA) trough levels (C(0)) and 2 hours after intake (C(2)) of CyA in human renal allograft recipients.
    Böhler T; Budde K; Schneider M; Eliazyfer S; Dell K; Einecke G; Diekmann F; Fritsche L; Mai I; Neumayer HH; Waiser J
    Transplant Proc; 2001; 33(7-8):3148-50. PubMed ID: 11750352
    [No Abstract]   [Full Text] [Related]  

  • 2. Profibrotic cytokines and lymphocyte proliferation in stable renal allograft recipients treated with or without cyclosporine A.
    Waiser J; Schneider M; Eljazyfer S; Slowinski T; Glander P; Einecke G; Budde K; Neumayer HH; Böhler T
    Clin Immunol; 2006 Apr; 119(1):59-66. PubMed ID: 16451828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients.
    Einecke G; Mai I; Diekmann F; Fritsche L; Neumayer HH; Budde K
    Transplant Proc; 2002 Aug; 34(5):1738-9. PubMed ID: 12176557
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients.
    Ferraresso M; Citterio F; Ghio L; Romagnoli J; Edefonti A; Berardinelli L; Castagneto M
    Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients.
    Einecke G; Mai I; Diekmann F; Fritsche L; Boehler T; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3102-3. PubMed ID: 11750333
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
    Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
    Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of trough level and C(2) cyclosporine blood concentration monitoring in outpatient kidney transplant recipients.
    Braun F; Armstrong VW; Lorf T; Canelo R; Arndt C; Oellerich M; Ringe B
    Transplant Proc; 2001; 33(7-8):3108-9. PubMed ID: 11750336
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolution of the therapeutic drug monitoring of cyclosporine.
    Citterio F
    Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cyclosporine microemulsion in Pakistani renal allograft recipients: correlation of trough peak levels with 7-point and 3-point AUC.
    Hussain M; Zafar N; Bux A; Sultan S; Hashmi A; Hussain Z; Hafiz S; Naqvi A; Rizvi A
    Transplant Proc; 1998 Nov; 30(7):3555. PubMed ID: 9838556
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients.
    Budde K; Braun KP; Glander P; Böhler T; Hambach P; Fritsche L; Waiser J; Mai I; Neumayer HH
    Transplant Proc; 2002 Aug; 34(5):1748-50. PubMed ID: 12176561
    [No Abstract]   [Full Text] [Related]  

  • 12. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
    Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
    Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of abbreviated AUC of cyclosporine in renal allograft recipients in a Pakistani population.
    Zafar MN; Abbas K; Naqvi A; Rizvi A
    Transplant Proc; 1999 Dec; 31(8):3304. PubMed ID: 10616486
    [No Abstract]   [Full Text] [Related]  

  • 15. TGF-beta: a link between immunosuppression, nephrotoxicity, and CsA.
    Khanna AK; Cairns VR; Becker CG; Hosenpud JD
    Transplant Proc; 1998 Jun; 30(4):944-5. PubMed ID: 9636380
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical assessment of trough levels for monitoring of rejection in cyclosporine-treated kidney transplant recipients.
    Takahara S; Namiki M; Kokado Y; Kameoka H; Okuyama A
    Int Urol Nephrol; 1996; 28(3):431-8. PubMed ID: 8899485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of changing therapeutic cyclosporine monitoring from C(0) to C(2) in stable renal recipients: narrower coefficient of variation with C(2) monitoring.
    Chueh SC; Liao CH; Chang CJ; Lai MK
    Transplant Proc; 2001; 33(7-8):3100-1. PubMed ID: 11750332
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete withdrawal of immunosuppression in kidney allograft recipients: a prospective study in rhesus monkeys.
    Jonker M; van den Hout Y; Neuhaus P; Ringers J; Kuhn EM; Bruijn JA; Schuurman HJ; Noort R; Bontrop RE; Claas FH; van Rood JJ
    Transplant Proc; 1998 Aug; 30(5):2451-3. PubMed ID: 9723534
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunity in maintenance immunosuppression with and without cyclosporine in long-term kidney transplant recipients.
    Yamashita M; Aikawa A
    Transplant Proc; 2000 Nov; 32(7):1768-72. PubMed ID: 11119927
    [No Abstract]   [Full Text] [Related]  

  • 20. Calcineurin activity in children with renal transplants receiving cyclosporine.
    Quien RM; Kaiser BA; Dunn SP; Kulinsky A; Polinsky M; Baluarte HJ; Batiuk TD; Halloran PF
    Transplantation; 1997 Nov; 64(10):1486-9. PubMed ID: 9392319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.